It is not approved for human or veterinary use, clinical administration, therapeutic applications, or diagnostic procedures of any kind
Krzak Ilona gygyszersszel kzsen sszelltottuk a legfontosabb tudnivalkat rla
Our Doctors Meet Our Team of Doctors and Medical Professionals
doi:10.1186/s12875-019-1070-0
A combination of an amylin analog, cagrilintide, and semaglutide known as CargiSema, is a single weekly injection under development by Novo Nordisk, with phase 3a results published in 2025
This package includes semaglutide injections, bi-weekly Lipo Mino injections, the Balance D dietary supplement, board-certified physician oversight, nutrition counseling, wellness coaching with one monthly call and daily messaging access, and online fitness training three times per week